SEP 28, 2021 8:00 AM PDT

Cell Therapy Scrubs Tumors, Spares Transplanted Organs

WRITTEN BY: Tara Fernandez

Hepatitis B infections have created a ‘silent epidemic’—infected people don’t display any symptoms, and as a consequence, unknowingly pass the virus on to others. The signs of hepatitis B virus (HBV) infection only manifest years after the initial infection. Many patients present with a common form of liver cancer called hepatocellular carcinoma or HCC.

At this critical stage, liver transplants provide HCC patients with the best hope. However, traces of the HBV in circulation still linger, which can return with a vengeance, only to reignite cancer in the newly-transplanted liver. 

Consequently, HBV-positive HCC patients who have received liver transplants have very few viable options to keep them cancer-free. This is partly because these individuals need to take a life-long regimen of immunosuppressive drugs to prevent their immune systems from rejecting the donor organ.

Cell therapies using reprogrammed T cells are available clinically—the patient’s immune cells are directed to target and eliminate tumor cells. However, immunosuppressive drugs taken by HCC patients would not discriminate against these ‘good’ immune cells, disarming them and reducing the efficacy of T cell therapies.

Now, researchers have developed T cell soldiers with specialized skills and strong, protective shields. A team led by Antonio Bertoletti from the Singapore Immunology Network (SIgN), developed next-generation T cell therapies that are resistant to immunosuppressive drugs. These unique T cells have been genetically manipulated such that they recognize and target liver cancer cells that contain fragments of HBV proteins. 

In their study, the researchers found that the commonly prescribed immunosuppressive drugs (tacrolimus and mofetil) were toxic to first-generation T cell therapies. However, by equipping T cells with a specific panel of genes, the turbocharged next-generation cells could maintain their cancer-killing capabilities even in the presence of harsh immunosuppressants.

This discovery paves the way for a new class of T cell therapies for HBV-positive patients with HCC that can eliminate tumors while leaving healthy liver tissues untouched.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 19, 2021
Immunology
Insights Into the Interplay Between COVID and the Nasal Microbiome
AUG 19, 2021
Insights Into the Interplay Between COVID and the Nasal Microbiome
There is a spectrum of COVID symptom severity: some recover after experiencing nothing more than a mild cough, while oth ...
AUG 24, 2021
Health & Medicine
Myocarditis and COVID-19 Vaccination
AUG 24, 2021
Myocarditis and COVID-19 Vaccination
Myocarditis has been linked to sudden cardiac death in young, healthy athletes and smallpox, influenza, hepatitis B, and ...
SEP 14, 2021
Immunology
The Spleen Creates Long-Lasting Protection Against the Flu Virus
SEP 14, 2021
The Spleen Creates Long-Lasting Protection Against the Flu Virus
You share an elevator with an individual who is coughing and sneezing, only to find yourself feeling unwell a few days l ...
SEP 23, 2021
Cardiology
Curbing Adverse Cardiovascular Outcomes Through Influenza Vaccination
SEP 23, 2021
Curbing Adverse Cardiovascular Outcomes Through Influenza Vaccination
Influenza is a severe infectious disease. According to the Centers for Disease Control and Prevention the H1N1 strain of ...
OCT 05, 2021
Immunology
Inflammation Overload Triggers 'Microclots' in COVID Long-Haulers
OCT 05, 2021
Inflammation Overload Triggers 'Microclots' in COVID Long-Haulers
Months after COVID symptoms have subsided, some individuals continue to grapple with the lingering effects of the infect ...
OCT 12, 2021
Drug Discovery & Development
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
OCT 12, 2021
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
Researchers at Japan’s Osaka University recently developed and tested a novel vaccine that may protect a ...
Loading Comments...